ZAMBELLI ALBERTO

Pala, L., Merlo, F., Sala, I., Pagan, E., Oriecuia, C., Specchia, C., et al. (2025). Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 117(8), 1557-1564 [10.1093/jnci/djaf049]. Dettaglio

Provenzano, L., Dieci, M., Curigliano, G., Giuliano, M., Botticelli, A., Lambertini, M., et al. (2025). Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. ANNALS OF ONCOLOGY, 36(7 (July 2025)), 762-774 [10.1016/j.annonc.2025.03.023]. Dettaglio

Canzian, J., Gentile, D., De Sanctis, R., Jacobs, F., Benvenuti, C., Gaudio, M., et al. (2025). Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients. THE ONCOLOGIST, 30(5) [10.1093/oncolo/oyaf061]. Dettaglio

Gori, S., Fabi, A., Procopio, G., Airoldi, M., Zambelli, A., Lanzetta, G., et al. (2025). Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway. ONCOLOGY AND THERAPY, 13(2), 505-517 [10.1007/s40487-025-00343-5]. Dettaglio

Lorini, L., Gili, R., Resteghini, C., Gerosa, R., Cecchi, L., Gurizzan, C., et al. (2025). Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer. ORAL ONCOLOGY, 164(May 2025) [10.1016/j.oraloncology.2025.107296]. Dettaglio